Companies / 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

Nasdaq: FDMTCIK 1650648EMERYVILLE, CA

Financials · FY2025

Revenue$85.21M
Net income$-140.11M
Total debt$19.59M
Cash$70.37M
Diluted EPS$-2.42
Shares outstanding69.2M

Ownership

69.2M shares outstanding · as of May 4, 2026
5.3%10%+ / strategic
Ownership
75.5%Common Stock
Share classes
Common Stock75.53%
Common Stock24.47%
10%+ / strategic5.27%3,650,737
Institutions70.64%48,892,307
Public float24.08%16,668,875

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 6

View all →
Insider% of sharesShares
Gupta AshooFormerVP, Finance and Controller
0.07%47,055
Bizily ScottFormerChief Legal Officer
——
Kirn DavidCEOChief Executive Officer · Director
——
Milligan John FDirector
——
Sblendorio GlennDirector
——
Simms Christopher PaulFormerSee Remarks
——

Institutional holders 158

View all →
HolderValue% of shares
BlackRock, Inc.$60.46M6.57%
Janus Henderson Group PLC$48.87M7.58%
RA Capital Management, L.P.$47.01M7.30%
State Street Corporation$38.72M4.21%
Novo Holdings A/S$33.99M5.27%
The Goldman Sachs Group, Inc.$32.27M6.22%
Bvf INC/IL$26.81M4.16%
Vanguard Group Inc$23.20M4.47%
Adage Capital Partners Gp, L.L.C.$14.94M2.32%
Armistice Capital, LLC$14.52M2.80%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 20, 2026Gupta Ashoo
Executive
SellCommon Stock$2.7K-310
-0.66%
46,914
0.07% of shares
low
Mar 20, 2026Gupta Ashoo
Executive
SellCommon Stock$689-80
-0.17%
47,055
0.07% of shares
low
Jun 17, 2026Sblendorio Glenn
Director
GrantStock Option (Right to Buy)—+50K
50,000
0.07% of shares
low
Jun 17, 2026Milligan John F
Director
GrantStock Option (Right to Buy)—+75K
75,000
0.11% of shares
low
Mar 25, 2026Bizily Scott
Executive
GrantStock Option (Right to Buy)—+217K
217,000
0.31% of shares
low
Mar 25, 2026Simms Christopher Paul
Executive
GrantStock Option (Right to Buy)—+219K
219,000
0.32% of shares
low
Mar 25, 2026Kirn David
CEO
GrantStock Option (Right to Buy)—+750K
750,000
1.08% of shares
low
Mar 20, 2026Gupta Ashoo
Executive
ExerciseRestricted Stock Units—-221
-6.68%
3,087
<0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—0—
Janus Henderson Group PLCPassive13G———
RA Capital Management, L.P.Passive13G/A———
Novo Holdings A/SPassive13G/A—3,650,737—
The Goldman Sachs Group, Inc.Passive13G/A———
Biotechnology Value Fund L PPassive13G/A———
Janus Henderson Group PLCPassive13G/A———
RA Capital Management, L.P.Passive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
FDMT——35104E100—